MediSpectra Begins Cervical Imaging Pivotal Study On Strength Of Pilot Data
This article was originally published in The Gray Sheet
Executive Summary
MediSpectra is conducting a pivotal U.S. trial comparing its Luma cervical imaging detection system as an adjunct to colposcopy with colposcopy alone
You may also be interested in...
MediSpectra Cervical Imaging System Gains FDA Panel Review
FDA's Obstetrics & Gynecology Devices Panel will meet on May 17 to review data from a 13-site, 2,200-woman trial for MediSpectra's Luma spectroscopy-based cervical imaging system
MediSpectra Cervical Imaging System Gains FDA Panel Review
FDA's Obstetrics & Gynecology Devices Panel will meet on May 17 to review data from a 13-site, 2,200-woman trial for MediSpectra's Luma spectroscopy-based cervical imaging system
MediSpectra Luma Cervical Imaging System Granted Expedited Review
MediSpectra hopes itsLuma cervical imaging system PMA will be reviewed by FDA's Obstetrics & Gynecological Devices panel this fall and approved in early 2005